Institutional members access full text with Ovid®

Share this article on:

Surgery, Crohn's Disease, and the Biological Era: Has There Been an Impact?

Slattery, Eoin MD, MRCPI; Keegan, Denise RGN; Hyland, John MCh, FRCSI; O'Donoghue, Diarmuid MD, FRCPI; Mulcahy, Hugh E. MD, FRCPI

Journal of Clinical Gastroenterology: September 2011 - Volume 45 - Issue 8 - p 691–693
doi: 10.1097/MCG.0b013e318201ff96
ALIMENTARY TRACT: Original Articles

Introduction The management of Crohn's disease (CD) has changed considerably over the last 20 years. Immunomodulators and biological therapies now play a role in treating patients with CD, but little is known of their influence on surgical rates.

Aim To review the surgery rates for CD in an Irish university hospital over a 20-year period and to determine whether newer therapies had an impact on surgical rates.

Method Seven hundred twenty-two patients attending St Vincent's University Hospital, Dublin, with CD over a 20-year period (January 1986 to December 2005) were identified. The patients were divided into quartiles. Resection rates were determined in all the quartiles, at both 1 and 3 years from diagnosis.

Results A decline in surgery, 3 years from diagnosis, was noted between the first quartile (72 patients, 40%) and the second quartile (58 patients, 32%; P=0.03). No significant change in surgical rates at 3 years occurred between the other 3 quartiles (32%, 30%, and 35%, respectively; P=NS). The patients who required a resection within 3 years were diagnosed at a younger age in later years. There was a similar predominance of 60% of female patients requiring surgery in all groups. The patients requiring surgery were twice as likely to be ex-smokers or current smokers in all groups. Use of infliximab, within 3 years from diagnosis, increased from 0, 0, and 16 patients (8.8%) to 40 patients (22.1%) in the last quartile. The majority of patients were treated with infliximab on an “on demand” basis. Use of infliximab earlier within the course of the disease was seen in later quartiles (ie, within 1 y of diagnosis): 0, 0, 6, and 21 patients.

Conclusion Despite the introduction of infliximab over the past 10 years, no demonstrable difference has been seen in the rates of patients requiring resection surgery within 3 years of diagnosis. The reasons for this are unclear, but may relate to episodic treatment, rather than regular maintenance treatment. Female patients and smokers seem to be particularly at risk of resection surgery.

Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland

The authors have no conflicts of interest or financial disclosures.

Reprints: Eoin Slattery, MD, MRCPI, Centre for Colorectal Disease, St Vincent's University Hospital, Dublin 4, Ireland (e-mail:

Received June 22, 2010

Accepted October 13, 2010

© 2011 Lippincott Williams & Wilkins, Inc.